Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 198 Carcinoma, Non-Small-Cell Lung 117 Breast Neoplasms 103 Glioblastoma 76 Ovarian Neoplasms 75 Carcinoma, Hepatocellular 58 Rectal Neoplasms 57 Brain Neoplasms 51 Neoplasm Metastasis 49 Neoplasms 46 Lung Neoplasms 46 Colonic Neoplasms 44 Glioma 37 Fallopian Tube Neoplasms 31 Gliosarcoma 30 Carcinoma, Renal Cell 29 Adenocarcinoma of Lung 25 Melanoma 24 Recurrence 21 Liver Neoplasms 21 Stomach Neoplasms 20 Pancreatic Neoplasms 20 Uterine Cervical Neoplasms 19 Triple Negative Breast Neoplasms 18 Esophageal Neoplasms 15 Endometrial Neoplasms 15 Kidney Neoplasms 14 Astrocytoma 13 Adenocarcinoma, Bronchiolo-Alveolar 13 Adenocarcinoma 12

Interventions

nimotuzumab 1 atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡